Status: Recruiting
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any documented EGFR-mutant locally advanced or metastatic NSCLC.
Participants needed: 110
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: EpiBiologicsUpdated: Jun 10, 2026Locations: 6
Eligibility criteria
Participant has a life expectancy > 12 weeks at Day 1. [+4]
Participant has history of uncontrolled illness. [+2]